217 related articles for article (PubMed ID: 16327320)
1. Increased risk of pre-eclampsia and fetal death in HIV-infected pregnant women receiving highly active antiretroviral therapy.
Suy A; Martínez E; Coll O; Lonca M; Palacio M; de Lazzari E; Larrousse M; Milinkovic A; Hernández S; Blanco JL; Mallolas J; León A; Vanrell JA; Gatell JM
AIDS; 2006 Jan; 20(1):59-66. PubMed ID: 16327320
[TBL] [Abstract][Full Text] [Related]
2. The AmRo study: pregnancy outcome in HIV-1-infected women under effective highly active antiretroviral therapy and a policy of vaginal delivery.
Boer K; Nellen JF; Patel D; Timmermans S; Tempelman C; Wibaut M; Sluman MA; van der Ende ME; Godfried MH
BJOG; 2007 Feb; 114(2):148-55. PubMed ID: 17305888
[TBL] [Abstract][Full Text] [Related]
3. Risk of Preeclampsia in Human Immunodeficiency Virus-Infected Pregnant Women.
Sansone M; Sarno L; Saccone G; Berghella V; Maruotti GM; Migliucci A; Capone A; Martinelli P
Obstet Gynecol; 2016 Jun; 127(6):1027-1032. PubMed ID: 27159742
[TBL] [Abstract][Full Text] [Related]
4. Pre-eclampsia: the role of highly active antiretroviral therapy and immune markers.
Phoswa WN; Naicker T; Ramsuran V; Moodley J
Inflamm Res; 2019 Jan; 68(1):47-57. PubMed ID: 30276649
[TBL] [Abstract][Full Text] [Related]
5. Time to viral load suppression in antiretroviral-naive and -experienced HIV-infected pregnant women on highly active antiretroviral therapy: implications for pregnant women presenting late in gestation.
Aziz N; Sokoloff A; Kornak J; Leva NV; Mendiola ML; Levison J; Feakins C; Shannon M; Cohan D
BJOG; 2013 Nov; 120(12):1534-47. PubMed ID: 23924192
[TBL] [Abstract][Full Text] [Related]
6. The impact of highly active antiretroviral therapy on obstetric conditions: A review.
Sebitloane HM; Moodley D
Eur J Obstet Gynecol Reprod Biol; 2017 Mar; 210():126-131. PubMed ID: 28013100
[TBL] [Abstract][Full Text] [Related]
7. Hospitalizations of pregnant HIV-infected women in the USA prior to and during the era of HAART, 1994-2003.
Kourtis AP; Bansil P; McPheeters M; Meikle SF; Posner SF; Jamieson DJ
AIDS; 2006 Sep; 20(14):1823-31. PubMed ID: 16954723
[TBL] [Abstract][Full Text] [Related]
8. Pregnancy outcome in women infected with HIV-1 receiving combination antiretroviral therapy before versus after conception.
Machado ES; Hofer CB; Costa TT; Nogueira SA; Oliveira RH; Abreu TF; Evangelista LA; Farias IF; Mercadante RT; Garcia MF; Neves RC; Costa VM; Lambert JS
Sex Transm Infect; 2009 Apr; 85(2):82-7. PubMed ID: 18987014
[TBL] [Abstract][Full Text] [Related]
9. Maternal and obstetric complications among HIV-infected women treated with highly active antiretroviral treatment at a Regional Hospital in Durban, South Africa.
Sebitloane HM; Moodley J
Niger J Clin Pract; 2017 Nov; 20(11):1360-1367. PubMed ID: 29303121
[TBL] [Abstract][Full Text] [Related]
10. Association of HIV and highly active antiretroviral therapy with clinical and biochemical indices among women with pre-eclampsia.
Maharaj NR; Moodley J; Chuturgoon A
Int J Gynaecol Obstet; 2016 Sep; 134(3):304-8. PubMed ID: 27350229
[TBL] [Abstract][Full Text] [Related]
11. Antiretroviral therapy in pregnant women with advanced HIV disease and pregnancy outcomes in Abidjan, Côte d'Ivoire.
Ekouevi DK; Coffie PA; Becquet R; Tonwe-Gold B; Horo A; Thiebaut R; Leroy V; Blanche S; Dabis F; Abrams EJ
AIDS; 2008 Sep; 22(14):1815-20. PubMed ID: 18753864
[TBL] [Abstract][Full Text] [Related]
12. Effect of antiretroviral therapy on pregnancy outcome in HIV-1 positive women.
Kowalska A; Niemiec T; El Midaoui A; Burkacka E
Med Wieku Rozwoj; 2003; 7(4 Pt 1):459-68. PubMed ID: 15010556
[TBL] [Abstract][Full Text] [Related]
13. Risk of preeclampsia in HIV-positive pregnant women receiving HAART: a matched cohort study.
Boyajian T; Shah PS; Murphy KE
J Obstet Gynaecol Can; 2012 Feb; 34(2):136-141. PubMed ID: 22340062
[TBL] [Abstract][Full Text] [Related]
14. Effects of antiretroviral therapy on occurrence of pre-eclampsia.
Mawson AR
Lancet; 2003 Jan; 361(9354):347-8. PubMed ID: 12559889
[No Abstract] [Full Text] [Related]
15. Pre-eclampsia, antiretroviral therapy, and immune reconstitution.
Wimalasundera RC; Larbalestier N; Smith JH; de Ruiter A; McG Thom SA; Hughes AD; Poulter N; Regan L; Taylor GP
Lancet; 2002 Oct; 360(9340):1152-4. PubMed ID: 12387967
[TBL] [Abstract][Full Text] [Related]
16. Pregnancy and delivery outcomes of HIV infected women in Switzerland 2003-2008.
Aebi-Popp K; Lapaire O; Glass TR; Vilén L; Rudin C; Elzi L; Battegay M; Keiser O; de Tejada BM; Hoesli IM;
J Perinat Med; 2010 Jul; 38(4):353-8. PubMed ID: 20184398
[TBL] [Abstract][Full Text] [Related]
17. Perinatal outcomes, mitochondrial toxicity and apoptosis in HIV-treated pregnant women and in-utero-exposed newborn.
Hernàndez S; Morén C; López M; Coll O; Cardellach F; Gratacós E; Miró O; Garrabou G
AIDS; 2012 Feb; 26(4):419-28. PubMed ID: 22156962
[TBL] [Abstract][Full Text] [Related]
18. Association of HIV infection with spontaneous and iatrogenic preterm delivery: effect of HAART.
Lopez M; Figueras F; Hernandez S; Lonca M; Garcia R; Palacio M; Coll O
AIDS; 2012 Jan; 26(1):37-43. PubMed ID: 22008651
[TBL] [Abstract][Full Text] [Related]
19. Risk factors for preterm birth, low birth weight, and intrauterine growth retardation in infants born to HIV-infected pregnant women receiving zidovudine. Pediatric AIDS Clinical Trials Group 185 Team.
Lambert JS; Watts DH; Mofenson L; Stiehm ER; Harris DR; Bethel J; Whitehouse J; Jimenez E; Gandia J; Scott G; O'Sullivan MJ; Kovacs A; Stek A; Shearer WT; Hammill H; van Dyke R; Maupin R; Silio M; Fowler MG
AIDS; 2000 Jul; 14(10):1389-99. PubMed ID: 10930154
[TBL] [Abstract][Full Text] [Related]
20. Fetal cardiac biometry and function in HIV-infected pregnant women exposed to HAART therapy.
De la Calle M; Rodriguez R; Deirós L; Bartha JL
Prenat Diagn; 2015 May; 35(5):453-5. PubMed ID: 25512023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
